The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study.
about
The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseasesNovel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancerTranscriptome sequencing to detect gene fusions in cancerIntraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancerIntraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention.Improving intermittent androgen deprivation therapy: lessons learned from basic and translational researchRole of 5α-reductase inhibitors in benign prostatic diseases.Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy.Oral testosterone with and without concomitant inhibition of 5α-reductase by dutasteride in hypogonadal men for 28 days.5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.Prostate cancers detected during 5α-reductase inhibitor use are smaller, de-differentiated, but confined when compared to controls.5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal modelsTissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate CancerThe rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme?Early dutasteride monotherapy in men with detectable serum prostate-specific antigen levels following radical prostatectomy: A prospective trial.Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.Testosterone and dihydrotestosterone levels in the transition zone correlate with prostate volume.Is There a Future for Chemoprevention of Prostate Cancer?Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression.Pre-radiotherapy PSA progression is a negative prognostic factor in prostate cancer patients using 5‑alpha-reductase inhibitors.Prognostic influence of 5 alpha reductase inhibitors in patients with localized prostate cancer under active surveillance.
P2860
Q21285041-EBEABBD5-E96E-46C4-B88B-85F3C9F77F6FQ24299807-6D200B70-1255-4471-9847-DC72DE2585DAQ24653386-790D54B9-5627-46FE-908D-5F515F1DC9C2Q27005840-4A44B2F1-FABE-4183-886C-D6E3D75B6299Q27690719-A268C623-2012-49B5-99BC-BFE3B05D42C5Q33658285-E123CB2F-EF9F-48CA-B343-DDA27C519B7DQ33922371-456C6785-5D87-4FC2-B067-B12E3A563185Q34254296-946D9279-5F6B-4777-A2E4-DE9D76FA89B1Q34294888-023A0A13-EEB8-4AED-8F81-10B2DBD8066BQ34710289-103CF986-90DB-4591-8E03-43490BFAAE73Q34887797-1ECB1DC9-2EA2-4898-9F62-C54126A6D36AQ35553876-774EA694-3D33-48B7-8FA6-822A99EF2494Q35815992-465AAB6E-A82E-4F70-BC95-6F9471A5F097Q36946035-AEB95F11-BF0E-451D-B5A8-D8029399A958Q37009071-E4A4B4B5-C066-470F-8839-ECF72C06C21AQ37086672-46F62E03-45AD-4F38-9388-07061972CBBEQ37526440-30707BA6-4FC3-4B9D-95D6-F4762A9CA8B8Q37671710-E8A1D1D2-B38F-4577-B69A-447EEB775AA5Q38733910-269A0F5C-27B2-4381-B182-C2147066DECBQ38736795-21315EC7-AB70-4824-8A94-735E68F8C0ACQ38878301-055FDC71-7579-4905-AE2F-B1BCE2F3B768Q39771305-0F92EE87-B3FB-490C-8244-911652A143AEQ48147954-2A281422-AECA-4E18-AE83-CDCAF98DFA30Q52670853-88950DBD-8232-46C6-8AA9-080697F1B363
P2860
The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The effects of the dual 5alpha ...... e-radical prostatectomy study.
@ast
The effects of the dual 5alpha ...... e-radical prostatectomy study.
@en
The effects of the dual 5alpha ...... e-radical prostatectomy study.
@nl
type
label
The effects of the dual 5alpha ...... e-radical prostatectomy study.
@ast
The effects of the dual 5alpha ...... e-radical prostatectomy study.
@en
The effects of the dual 5alpha ...... e-radical prostatectomy study.
@nl
prefLabel
The effects of the dual 5alpha ...... e-radical prostatectomy study.
@ast
The effects of the dual 5alpha ...... e-radical prostatectomy study.
@en
The effects of the dual 5alpha ...... e-radical prostatectomy study.
@nl
P2093
P356
P1433
P1476
The effects of the dual 5alpha ...... e-radical prostatectomy study.
@en
P2093
Bostwick D
Fleshner N
Pommerville P
Rittmaster R
Steinhoff G
P304
P356
10.1002/PROS.20499
P577
2006-11-01T00:00:00Z